[Treatment of scabies and Ascabiol(®) supply disruption: what about the pediatric population?].

Abstract

Scabies is a disease in steady increase in Île-de-France region. Standard treatment, Ascabiol(®) (benzyl benzoate/sulfiram), is back-order for several months and its return remains uncertain. Facing this drug shortage, French Drug Agency (ANSM) has imported a drug from Germany, Antiscabiosum 10 % (benzyl benzoate), to treat patients having contraindications for other scabicides available in France (ivermectin, esdepallethrine). However, infants less than 1 year (<15 kg) and asthmatics infants have no alternative treatment. A multidisciplinary workgroup explored the various existing therapeutic alternatives in France and worldwide. From ANSM's recommendations and group's experience, a decision algorithm was proposed for treating patients. However, pediatric context implied the use of off-label drugs. Proposed treatments widely known by practitioners, prescriptions-types, dose, modalities of use and dispensation, and flyers to patients were realized to optimize treatment efficacy.

• Authors: A Berthe-Aucejo, S Prot-Labarthe, L Pull, M Lorrot, S Touratier, H Trout, O Bourdon, L Dehen, E Bourrat
• Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (Arch Pediatr) Vol. 21 Issue 6 Pg. 670-5 (Jun 2014) ISSN: 1769-664X [Electronic] France
• Vernacular Title: Traitement de la gale et rupture d'Ascabiol(®) : quid de la population pédiatrique ? Gale chez l'enfant et rupture d'Ascabiol(®)
• PMID: 24768069 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Chemical References

• Benzoates
• Insecticides
• Permethrin
• Ivermectin
• benzyl benzoate

Topics

• Benzoates (supply & distribution, therapeutic use)
• Child
• Disinfection
• France
• Government Agencies
• Humans
• Insecticides (supply & distribution, therapeutic use)
• Ivermectin (therapeutic use)
• Permethrin (therapeutic use)
• Scabies (drug therapy)